Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Stopped early · Phase 2

Conditions studied: Idiopathic Pulmonary Fibrosis

In brief

The primary objective of this study is to evaluate the long term safety and tolerability of simtuzumab (GS-6624) in participants with idiopathic pulmonary fibrosis (IPF) who had previously participated in Gilead clinical trial AB0024-201.

Key facts

Study ID

NCT01759511

Run by

Gilead Sciences

People needed

34

Starts

2012-10-18

Expected to finish

2016-02-19

Last updated by the study team

2017-04-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Arizona Pulmonary Specialists, Ltd. — Scottsdale, Arizona, United States
• University of California — Los Angeles, California, United States
• Stanford University Medical Center — Stanford, California, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• Medical University of South Carolina — Charleston, South Carolina, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.